Citius Pharmaceuticals, Inc. (CTXR) News
Follow Citius Pharmaceuticals, Inc. (CTXR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
LYMPHIR Wholesaler Shipments Rise 120% in Fiscal Q4
Citius Pharmaceuticals said U.S. wholesalers purchased 792 LYMPHIR units in fiscal Q4 2026, up 120% from the prior quarter. Prescribing centers ordered 950 vials, and 54 institutions had ordered the therapy as of the rel
EQUITY | Oct 26, 2026, 08:13 PM UTC
L
CTXR: LYMPHIR launch drives early revenue and creates an investment arbitrage opportunity
Citius Pharmaceuticals and Citius Oncology have launched LYMPHIR for CTCL, achieving early revenue and broad payer coverage. The company reports strong clinical results, a robust pipeline, and highlights an investment op
EQUITY | Sep 09, 2026, 07:54 PM UTC
L
Citius Oncology (CTXR) reports fiscal Q3 2026 results, business update
Citius Oncology, Inc. (CTXR) reports fiscal third quarter 2026 financial results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 14, 2026, 08:30 PM UTC
L
Citius Oncology Expands Board
Citius Oncology appoints Jonathan Peri as independent director
MNA | Aug 12, 2026, 12:01 PM UTC
H
Citius Oncology Reports Strong Cancer Treatment Momentum
Citius Oncology sees strong commercial momentum
EQUITY | Aug 05, 2026, 01:17 PM UTC